Andere Sprachen Nyrada Inc.

Aktien

Markt geschlossen - Australian S.E. Andere Börsenplätze 07:47:04 26.06.2024			% 5 Tage	% 1. Jan.
0,056 ^AUD	+3,70 %		-5,08 %	+154,55 %

08:42	Starke inländische Inflationsdaten drücken australische Aktien nach unten	MT
18.04.	Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024

Strong Domestic Inflation Data Push Down Australian Shares	08:42
Nyrada Partners with Rebion on Brain Injury Therapy Development	02:13
Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury	30.04.
Nyrada Begins Animal Testing on NYR-BI03 Brain Injury Program	10.04.
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	28.03.
Nyrada Raises AU$1.8 Million via Placement	06.03.
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2023	20.02.
Nyrada Secures AU$3.5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Surge 30%	08.12.
Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28.08.23
Australian Shares Flat as June Unemployment Rate Remains at 3.5%	20.07.23
Nyrada Halves Director Fees; Shares Jump 37%	20.07.23
Nyrada Opts to Advance NYR-BI03 Brain Injury Drug Candidate	12.06.23
Nyrada Completes Preclinical Studies on Cholesterol Lowering Medication	26.05.23
Nyrada Completes Preclinical Dose Formulation for Cholesterol Lowering Medication	11.04.23
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2022	24.02.23
Nyrada Extends R&D Deal for Brain Injury Drug Candidate	18.01.23
Nyrada Inc. Announces Collaboration with Walter Reed and UNSW Extended to 2025	17.01.23
Nyrada Advances Preclinical Studies for Brain Injury Drug Candidate	11.01.23
Nyrada Inc. Provides Update on the Progress of Its Brain Injury Program	10.01.23
Nyrada Receives $804,600 R&D Tax Refund; Shares fall 11%	18.11.22

Keine Ergebnisse zu dieser Suche